1 | N acetyl cysteine | 1件: Cysteine Cysteine | - | - | - | 1件: 19 19 |
2 | N Acetyl L Leucine | 1件: Leucine Leucine | 1件: D00030
D00030
| - | - | 1件: 19 19 |
3 | N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 |
4 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: D02601
D02601
| - | - | 1件: 127 127 |
5 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: D02601
D02601
| - | - | 1件: 127 127 |
6 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: D02601
D02601
| - | - | 1件: 127 127 |
7 | N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 |
8 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 |
9 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 |
10 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 |
11 | N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide | - | - | - | - | 1件: 299 299 |
12 | N-0923 | - | - | - | - | 1件: 6 6 |
13 | N-3 LC-PUFA | - | - | - | - | 1件: 46 46 |
14 | N-3 Polyunsaturated Fatty Acids | - | - | - | - | 1件: 96 96 |
15 | N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide | 2件: Acetamide Acetamide, Pyrazole | - | - | - | 1件: 154 154 |
16 | N-acetyl cysteine | 1件: Cysteine Cysteine | - | - | - | 6件: 13 13, 34, 85, 88, 296, 310 |
17 | N-Acetyl Cysteine (NAC) | 1件: Cysteine Cysteine | - | - | - | 1件: 90 90 |
18 | N-acetyl-cysteine | 1件: Cysteine Cysteine | - | - | - | 1件: 84 84 |
19 | N-Acetyl-L Leucine | 1件: Leucine Leucine | 1件: D00030
D00030
| - | - | 1件: 19 19 |
20 | N-Acetyl-L-Leucine | 2件: L-Acetylleucine L-Acetylleucine, Leucine | 1件: D00030
D00030
| - | - | 2件: 19 19, 65 |
21 | N-acetylcystein | - | - | - | - | 1件: 299 299 |
22 | N-Acetylcysteine | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 13件: 6 6, 13, 19, 20, 21, 49, 58, 85, 90, 111, 164, 299, 337 |
23 | N-acetylcysteine (NAC) | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 2件: 51 51, 299 |
24 | N-acetylcysteine capsule | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 6 6 |
25 | N-acetylcysteine syrup | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 53 53 |
26 | N-Acetylcysteine, (NAC) | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 85 85 |
27 | N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 |
28 | N-acetylneuraminic acid | - | - | - | - | 1件: 30 30 |
29 | N-Carbamylglutamate | 1件: Carglumic acid Carglumic acid | 1件: D07130
D07130
| 1件: CPS1 CPS1 💬 | 6件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Arginine biosynthesis, Biosynthesis of amino acids, Carbon metabolism, Metabolic pathways, Nitrogen metabolism 💬 | 2件: 245 245, 246 |
30 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 |
31 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 |
32 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | - | - | - | 1件: 265 265 |
33 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium | - | - | - | - | 1件: 96 96 |
34 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium | - | - | - | - | 1件: 96 96 |
35 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO | - | - | - | - | 1件: 11 11 |
36 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide, Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein, Hydroxide ion | 1件: D02416
D02416
| - | - | 1件: 11 11 |
37 | N. MENINGITIDIS GROUP C POLYSACCHARIDE | - | - | - | - | 1件: 14 14 |
38 | N. MENINGITIDIS GROUP W135 OLIGOSACCHARIDE CONJUGATED CRM197 | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 13 13 |
39 | N.a. | - | - | - | - | 10件: 3 3, 6, 8, 13, 46, 96, 97, 240, 256, 271 |
40 | N.d. | - | - | - | - | 1件: 97 97 |
41 | N02BG10 | - | - | - | - | 1件: 13 13 |
42 | N03AX12 | - | - | - | - | 1件: 13 13 |
43 | N04BA | - | - | - | - | 1件: 6 6 |
44 | N04BC07 | - | - | - | - | 1件: 6 6 |
45 | N04BD02 | - | - | - | - | 1件: 6 6 |
46 | N06DX01 | - | - | - | - | 1件: 13 13 |
47 | N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE | - | - | - | - | 2件: 5 5, 17 |
48 | N6022 | - | - | - | - | 1件: 299 299 |
49 | N91115 | - | - | - | - | 1件: 299 299 |
50 | Na | - | - | - | - | 3件: 36 36, 46, 85 |
51 | Na18F | - | - | - | - | 1件: 13 13 |
52 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 |
53 | NABILONE | 1件: Nabilone Nabilone | 1件: D05099
D05099
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 3件: 6 6, 13, 127 |
54 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: D05099
D05099
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 |
55 | Nabiximols | 1件: Nabiximols Nabiximols | 1件: D09317
D09317
| - | - | 1件: 13 13 |
56 | Nabiximols - Sativex | 2件: Dronabinol Dronabinol, Nabiximols | 2件: D00306
D00306
,
D09317
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
57 | NAC | - | - | - | - | 4件: 51 51, 85, 90, 299 |
58 | NAC effervescent tablets | - | - | - | - | 1件: 90 90 |
59 | NaCl | - | - | - | - | 1件: 227 227 |
60 | NaCl 0.9% | - | - | - | - | 1件: 39 39 |
61 | Nacom | - | - | - | - | 1件: 6 6 |
62 | NACOM 100 | - | - | - | - | 1件: 6 6 |
63 | NACOM levodopa+cardidopa | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
64 | Nacystelyn | - | - | - | - | 1件: 299 299 |
65 | Nacystelyn® | - | - | - | - | 1件: 299 299 |
66 | NADH | 1件: NADH NADH | - | - | - | 1件: 302 302 |
67 | Nadolol | 1件: Nadolol Nadolol | 1件: D00432
D00432
| 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
68 | Naglazyme | 1件: Galsulfase Galsulfase | 1件: D06565
D06565
| 1件: ARSB ARSB 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
69 | Naglazyme (galsulfase) | 1件: Galsulfase Galsulfase | 1件: D06565
D06565
| 1件: ARSB ARSB 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
70 | Naglazyme® | 1件: Galsulfase Galsulfase | 1件: D06565
D06565
| 1件: ARSB ARSB 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
71 | NAL | - | - | - | - | 2件: 6 6, 299 |
72 | Nalbuphine | 1件: Nalbuphine Nalbuphine | 1件: D08246
D08246
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
73 | Nalbuphine ER | 1件: Nalbuphine Nalbuphine | 1件: D08246
D08246
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
74 | Nalbuphine Extended-Realease (ER) Tablets | 1件: Nalbuphine Nalbuphine | 1件: D08246
D08246
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
75 | Nalbuphine Extended-Release (ER) Tablets | 1件: Nalbuphine Nalbuphine | 1件: D08246
D08246
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
76 | NALBUPHINE HYDROCHLORIDE | 1件: Nalbuphine Nalbuphine | 1件: D08246
D08246
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
77 | Nalmefene | 1件: Nalmefene Nalmefene | 1件: D05111
D05111
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
78 | Naloxone | 1件: Naloxone Naloxone | 1件: D08249
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 6 6, 226 |
79 | NALOXONE HYDROCHLORIDE | 1件: Naloxone Naloxone | 1件: D08249
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
80 | NALOXONE HYDROCHLORIDE DIHYDRATE | 1件: Naloxone Naloxone | 1件: D08249
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
81 | Naltrexone | 1件: Naltrexone Naltrexone | 1件: D05113
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 12件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 |
82 | NALTREXONE CLORIDRATO | 1件: Naltrexone Naltrexone | 1件: D05113
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 10 10 |
83 | NALTREXONE HYDROCHLORIDE | 1件: Naltrexone Naltrexone | 1件: D05113
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 8件: 10 10, 40, 41, 42, 43, 44, 45, 96 |
84 | Naltrexone-HCl | 1件: Naltrexone Naltrexone | 1件: D05113
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 96 96 |
85 | NAMILUMAB | 1件: Namilumab Namilumab | - | - | - | 2件: 46 46, 84 |
86 | Namilumab (MT203) | 1件: Namilumab Namilumab | - | - | - | 1件: 46 46 |
87 | Namisol | - | - | - | - | 2件: 13 13, 298 |
88 | Namuscla | 1件: Mexiletine Mexiletine | 1件: D08215
D08215
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 114 114 |
89 | NAND (Neoandrographolide) | - | - | - | - | 1件: 97 97 |
90 | Nandrolone | 1件: Nandrolone Nandrolone | 1件: D08250
D08250
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 2件: 60 60, 85 |
91 | Nandrolone Decanoate | 2件: Nandrolone Nandrolone, Nandrolone decanoate | 2件: D00955
D00955
,
D08250
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 2件: 60 60, 85 |
92 | Nanobody directed towards the human A1 domain of von Willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 |
93 | Nanobubble drink | - | - | - | - | 1件: 46 46 |
94 | Nanocort | - | - | - | - | 3件: 13 13, 46, 97 |
95 | Nanocurcumin | - | - | - | - | 2件: 13 13, 271 |
96 | Nanogam | - | - | - | - | 1件: 63 63 |
97 | Nanogam 100 mg/ml | - | - | - | - | 1件: 65 65 |
98 | Nanogam® 50 mg/ml | - | - | - | - | 1件: 65 65 |
99 | Nanoparticulated Rebamipide | 1件: Rebamipide Rebamipide | 1件: D01121
D01121
| - | - | 1件: 46 46 |
100 | Nanosuspension) | - | - | - | - | 1件: 113 113 |
101 | Nap | - | - | - | - | 2件: 96 96, 240 |
102 | NaPBA | - | - | - | - | 1件: 251 251 |
103 | Naprosyn | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 |
104 | Naprosyn 500 mg | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
105 | Naprosysn | - | - | - | - | 1件: 271 271 |
106 | Naproxen | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 4件: 13 13, 46, 107, 271 |
107 | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
108 | Naproxen 10 mg/kg | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
109 | Naproxen 500 mg tablets (PN 200 minus omeprazole) | 2件: Naproxen Naproxen, Omeprazole | 2件: D00118
D00118
,
D00455
| 4件: ATP4A ATP4A, ATP4B, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 46 46, 271 |
110 | Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
111 | Naproxen oral suspension | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
112 | NAPROXEN SODIUM | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 107 107 |
113 | Naproxen sodium 550mg tablet | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
114 | Nardil | 1件: Phenelzine Phenelzine | 1件: D08349
D08349
| 2件: MAOA MAOA, MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
115 | Narsoplimab | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 66 66, 222 |
116 | Nasal Aztreonam | 1件: Aztreonam Aztreonam | 1件: D00240
D00240
| - | - | 1件: 299 299 |
117 | Nasonex | - | - | - | - | 1件: 98 98 |
118 | Nasopharyngeal swabs | - | - | - | - | 1件: 46 46 |
119 | NATALIZUMAB | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 5件: 13 13, 15, 25, 46, 96 |
120 | Natalizumab (BG00002) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
121 | Natalizumab (NTZ) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
122 | Natalizumab (Tysabri) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
123 | Natalizumab 300 MG in 15 ML Injection | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
124 | Natalizumab for IV Infusion | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
125 | Natalizumab for Subcutaneous Injection | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
126 | Natalizumab Injection [Tysabri] | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
127 | Natalizumab IV | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
128 | Natalizumab SC | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
129 | Natalizumab treatment | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
130 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 |
131 | Natpar | 1件: Parathyroid hormone Parathyroid hormone | 1件: D05364
D05364
| 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
132 | Natpara | - | - | - | - | 1件: 235 235 |
133 | NATPARA/NATPAR | 1件: Parathyroid hormone Parathyroid hormone | 1件: D05364
D05364
| 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
134 | Natriumchlorid | 1件: Sodium chloride Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 288 288 |
135 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 288 288 |
136 | Natriumklorid 9mg/ml | - | - | - | - | 1件: 46 46 |
137 | Natriuretic peptide | - | - | - | - | 1件: 276 276 |
138 | Natrunix | - | - | - | - | 1件: 46 46 |
139 | Navocaftor | - | - | - | - | 1件: 299 299 |
140 | NBI-5788 | - | - | - | - | 1件: 13 13 |
141 | NBI-74788 | - | - | - | - | 1件: 81 81 |
142 | NBI-77860 | - | - | - | - | 1件: 81 81 |
143 | NBI-827104 | - | - | - | - | 1件: 154 154 |
144 | NBMI | - | - | - | - | 2件: 5 5, 17 |
145 | NBT-NM108 | - | - | - | - | 1件: 193 193 |
146 | NBT-NM108 (60 g/day) | - | - | - | - | 1件: 13 13 |
147 | NBTX-001 | - | - | - | - | 1件: 6 6 |
148 | NC 1 cell therapy | - | - | - | - | 1件: 117 117 |
149 | NC-503 (Anti-amyloidotic (AA) Agent) | - | - | - | - | 1件: 46 46 |
150 | NCA 500mg | - | - | - | - | 1件: 93 93 |
151 | Nd | - | - | - | - | 6件: 2 2, 6, 13, 46, 51, 97 |
152 | ND-L02-s0201 | - | - | - | - | 1件: 85 85 |
153 | ND-L02-s0201 for injection | - | - | - | - | 1件: 85 85 |
154 | ND0611 | - | - | - | - | 1件: 6 6 |
155 | ND0612 | - | - | - | - | 1件: 6 6 |
156 | ND0612 (Levodopa/Carbidopa solution) | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
157 | ND1421 | - | - | - | - | 1件: 6 6 |
158 | ND1587 | - | - | - | - | 1件: 6 6 |
159 | ND1589 | - | - | - | - | 1件: 6 6 |
160 | ND1590 | - | - | - | - | 1件: 6 6 |
161 | ND1702 | - | - | - | - | 1件: 6 6 |
162 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 |
163 | NDV-3A | - | - | - | - | 1件: 65 65 |
164 | NE3107 | - | - | - | - | 1件: 6 6 |
165 | NEB/01-07 | - | - | - | - | 1件: 299 299 |
166 | Nebcin | - | - | - | - | 1件: 299 299 |
167 | Nebcin (tobramycin) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
| - | - | 1件: 299 299 |
168 | Nebcinal | - | - | - | - | 1件: 299 299 |
169 | Nebcinal Tobi | - | - | - | - | 1件: 299 299 |
170 | NEBCINE | - | - | - | - | 1件: 299 299 |
171 | Nebicapone | 1件: Nebicapone Nebicapone | - | - | - | 1件: 6 6 |
172 | Nebido | - | - | - | - | 1件: 13 13 |
173 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: D00075
D00075
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
174 | Nebivolol | 1件: Nebivolol Nebivolol | 1件: D05127
D05127
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 17 17, 85, 113, 167 |
175 | Nebivolol 5 mg | 1件: Nebivolol Nebivolol | 1件: D05127
D05127
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 |
176 | Nebulization of Amikacin during NIV (RR: 15 cycles/minute) | 1件: Amikacin Amikacin | 1件: D02543
D02543
| - | - | 1件: 299 299 |
177 | Nebulization of Amikacin during NIV (RR: 25 cycles/minute) | 1件: Amikacin Amikacin | 1件: D02543
D02543
| - | - | 1件: 299 299 |
178 | Nebulization tobramycin | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
| - | - | 1件: 299 299 |
179 | Nebulized combination ipratropium bromide with salbutamol | 2件: Ipratropium Ipratropium, Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
180 | Nebulized ipratropium bromide | 1件: Ipratropium Ipratropium | - | - | - | 1件: 86 86 |
181 | Necator americanus | - | - | - | - | 1件: 13 13 |
182 | Nedosiran | - | - | - | - | 1件: 234 234 |
183 | Needle biopsy of the vastus lateralis muscle | - | - | - | - | 1件: 113 113 |
184 | NEFECON | - | - | - | - | 1件: 66 66 |
185 | Neflamapimod | 1件: Neflamapimod Neflamapimod | 1件: D10959
D10959
| 4件: MAPK11 MAPK11, MAPK12, MAPK13, MAPK14 💬 | 62件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Alcoholic liver disease, Amyotrophic lateral sclerosis, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dopaminergic synapse, Endocrine resistance, Epithelial cell signaling in Helicobacter pylori infection, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hepatitis B, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Oocyte meiosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Platelet activation, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Relaxin signaling pathway, Retrograde endocannabinoid signaling, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Yersinia infection 💬 | 1件: 8 8 |
186 | NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 |
187 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 50 50 |
188 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 |
189 | Nelfinavir | 1件: Nelfinavir Nelfinavir | 1件: D08259
D08259
| - | - | 3件: 49 49, 265, 331 |
190 | Nelfinavir mesylate | 1件: Nelfinavir Nelfinavir | 1件: D08259
D08259
| - | - | 1件: 265 265 |
191 | Nelotanserin | 1件: Nelotanserin Nelotanserin | 1件: D09645
D09645
| 1件: HTR2A HTR2A 💬 | 5件: Calcium signaling pathway Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse 💬 | 1件: 6 6 |
192 | Nelutri™ | - | - | - | - | 1件: 84 84 |
193 | Nemolizumab | 1件: Nemolizumab Nemolizumab | 1件: D11080
D11080
| 1件: IL31RA IL31RA 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 51 51 |
194 | Neo-ASA | - | - | - | - | 1件: 251 251 |
195 | NEO-GAA | - | - | - | - | 1件: 256 256 |
196 | Neo-Recormon | - | - | - | - | 1件: 18 18 |
197 | NEOD001 | - | - | - | - | 1件: 28 28 |
198 | NeoFuse | - | - | - | - | 1件: 70 70 |
199 | NeoGAA | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: D11744
D11744
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
200 | NeoGAA or avalglucosidase alfa | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: D11744
D11744
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
201 | Neomycin | 1件: Neomycin Neomycin | 1件: D08260
D08260
| - | - | 3件: 96 96, 97, 296 |
202 | Neophyr 1000ppm mol/mol | - | - | - | - | 1件: 294 294 |
203 | Neoral | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 60 60, 97, 222 |
204 | Neoral Oral Solution | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 269 269 |
205 | Neoral Soft Gelatin Capsules | 2件: Cyclosporine Cyclosporine, Gelatin | 3件: D00115
D00115
,
D00184
,
D06892
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 97 97, 269 |
206 | NeoRecormon | - | - | - | - | 2件: 13 13, 18 |
207 | Neovasculgen | - | - | - | - | 1件: 51 51 |
208 | Neramexane | 1件: Neramexane Neramexane | - | - | - | 1件: 13 13 |
209 | Neramexane mesylate | 1件: Neramexane Neramexane | - | - | - | 1件: 13 13 |
210 | Neratinib | 1件: Neratinib Neratinib | 1件: D08950
D08950
| 3件: EGFR EGFR, ERBB2, ERBB4 💬 | 51件: Adherens junction Adherens junction, Amyotrophic lateral sclerosis, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Platinum drug resistance, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Tight junction 💬 | 1件: 34 34 |
211 | Neridronic Acid | 1件: Neridronic Acid Neridronic Acid | - | - | - | 1件: 6 6 |
212 | Nerispirdine | 1件: Nerispirdine Nerispirdine | - | - | - | 1件: 13 13 |
213 | Nerispirdine (HP184) | 1件: Nerispirdine Nerispirdine | - | - | - | 1件: 13 13 |
214 | Nerispirdine hydrochloride | 1件: Nerispirdine Nerispirdine | - | - | - | 1件: 13 13 |
215 | NERIXIA*IM EV 1F 25MG | - | - | - | - | 1件: 6 6 |
216 | NERIXIA*INFUS IV CONC 2F 100MG | - | - | - | - | 1件: 274 274 |
217 | Nerve block | - | - | - | - | 1件: 46 46 |
218 | Nerve Growt Factor - 2.5S | - | - | - | - | 1件: 90 90 |
219 | Nerve Growth Factor | 1件: Nerve Growth Factor Nerve Growth Factor | - | - | - | 3件: 3 3, 53, 90 |
220 | Nessuno | - | - | - | - | 1件: 96 96 |
221 | Neu-120 | - | - | - | - | 1件: 6 6 |
222 | Neumega (Oprelvekin, Interleukin 11, IL-11) | 1件: Oprelvekin Oprelvekin | 1件: D05266
D05266
| 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 |
223 | NEUPOGEN | - | - | - | - | 4件: 13 13, 28, 51, 285 |
224 | NEUPRO | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
225 | Neupro (Reference) | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
226 | NEUPRO 2 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
227 | Neupro 2 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
228 | Neupro 2mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
229 | Neupro 2mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
230 | NEUPRO 4 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
231 | Neupro 4 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
232 | Neupro 4mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
233 | Neupro 4mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
234 | Neupro 4Mg/24Hr Transdermal Patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
235 | NEUPRO 6 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
236 | Neupro 6 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
237 | Neupro 6mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
238 | Neupro 6mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
239 | NEUPRO 8 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
240 | Neupro 8 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
241 | Neupro 8mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
242 | NEUPRO*28CER 2MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
243 | NEUPRO*28CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
244 | NEUPRO*28CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
245 | NEUPRO*28CER 8MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
246 | NEUPRO*7CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
247 | NEUPRO*7CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
248 | NEUPRO*7CER 8MG/24H | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
249 | Neupro® | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
250 | Neupro® 8 mg/24 h | 1件: Rotigotine Rotigotine | 1件: D05768
D05768
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
251 | Neuraceq | 1件: Florbetaben (18F) Florbetaben (18F) | - | - | - | 1件: 6 6 |
252 | NEUROASPIS PLP10® | - | - | - | - | 1件: 13 13 |
253 | NEUROBLOC | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 |
254 | NeuroEPO | - | - | - | - | 1件: 6 6 |
255 | Neurological evaluation | - | - | - | - | 1件: 25 25 |
256 | NEURONTIN | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
257 | Neurontin 300 mg hard capsule | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
258 | NeuroVax | 1件: NeuroVax NeuroVax | - | - | - | 1件: 13 13 |
259 | NeuroVax 300ug/mL Dose for IM Injection | 1件: NeuroVax NeuroVax | - | - | - | 1件: 13 13 |
260 | Neurpro | - | - | - | - | 1件: 6 6 |
261 | Nevanimibe | 1件: Nevanimibe Nevanimibe | 1件: D11300
D11300
| - | - | 2件: 75 75, 81 |
262 | Nevanimibe hydrochloride | 1件: Nevanimibe Nevanimibe | 1件: D11300
D11300
| - | - | 2件: 75 75, 81 |
263 | Nevirapine | 1件: Nevirapine Nevirapine | 1件: D00435
D00435
| - | - | 1件: 265 265 |
264 | New formulation adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
265 | New Formulation Etanercept | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
266 | New Formulation of rebif - human interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
267 | New thermo stable formulation of epoprostenol sodium | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
268 | NewGam | - | - | - | - | 3件: 14 14, 63, 65 |
269 | Newnorm | - | - | - | - | 1件: 65 65 |
270 | Nexavar | 1件: Sorafenib Sorafenib | 1件: D08524
D08524
| 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 |
271 | Nexavar (BAY 43-9006) (Sorafenib) | 1件: Sorafenib Sorafenib | 1件: D08524
D08524
| 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 |
272 | Nexium | 1件: Esomeprazole Esomeprazole | 1件: D07917
D07917
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 299 299 |
273 | Nexium (esomeprazole magnesium) | 2件: Esomeprazole Esomeprazole, Magnesium | 1件: D07917
D07917
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 298 298 |
274 | Nexium 20 | 1件: Esomeprazole Esomeprazole | 1件: D07917
D07917
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 299 299 |
275 | Next generation sequencing | - | - | - | - | 1件: 171 171 |
276 | NFC-1 | - | - | - | - | 1件: 203 203 |
277 | NFX-179 Gel | - | - | - | - | 1件: 34 34 |
278 | NG-Monomethyl-L-arginine | 3件: Arginine Arginine, L-arginine, Tilarginine | 1件: D02982
D02982
| - | - | 1件: 67 67 |
279 | Ng-monomethyl-L-arginine (drug) | 2件: Arginine Arginine, Tilarginine | 1件: D02982
D02982
| - | - | 1件: 67 67 |
280 | Ngenla | 1件: Somatrogon Somatrogon | 1件: D10990
D10990
| - | - | 1件: 78 78 |
281 | NGENLA (Somatrogon) | 1件: Somatrogon Somatrogon | 1件: D10990
D10990
| - | - | 1件: 78 78 |
282 | NGM282 | - | - | - | - | 2件: 93 93, 94 |
283 | NGN-101 | - | - | - | - | 1件: 19 19 |
284 | NGX267 | 1件: NGX267 NGX267 | - | - | - | 1件: 53 53 |
285 | NI-0101 | - | - | - | - | 1件: 46 46 |
286 | NI-03 | - | - | - | - | 1件: 298 298 |
287 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 |
288 | NI-0501 | - | - | - | - | 1件: 107 107 |
289 | NI-071 | - | - | - | - | 1件: 46 46 |
290 | NI-0801 | - | - | - | - | 1件: 93 93 |
291 | Niacin | 1件: Niacin Niacin | 1件: D00049
D00049
| - | - | 2件: 6 6, 78 |
292 | Niacin First | 1件: Niacin Niacin | 1件: D00049
D00049
| - | - | 1件: 78 78 |
293 | Niacinamide | 1件: Nicotinamide Nicotinamide | 1件: D00036
D00036
| - | - | 3件: 5 5, 6, 67 |
294 | Nicardipine | 1件: Nicardipine Nicardipine | 1件: D08270
D08270
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 70 70, 86 |
295 | Niclosamide | 1件: Niclosamide Niclosamide | 1件: D00436
D00436
| - | - | 2件: 46 46, 97 |
296 | Nicolon | - | - | - | - | 1件: 97 97 |
297 | Nicorette 10mg/ 16 h | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 |
298 | Nicorette 15 mg/ 16 h | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 |
299 | Nicorette 5 mg/ 16 h | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 |
300 | Nicotinamid riboside | - | - | - | - | 1件: 13 13 |
301 | Nicotinamide | 1件: Nicotinamide Nicotinamide | 1件: D00036
D00036
| - | - | 8件: 2 2, 6, 18, 49, 97, 107, 162, 191 |
302 | Nicotinamide riboside | 2件: Nicotinamide Nicotinamide, Nicotinamide riboside | 1件: D00036
D00036
| - | - | 5件: 2 2, 6, 18, 97, 191 |
303 | Nicotinamide Riboside Chloride | 3件: Chloride ion Chloride ion, Nicotinamide, Nicotinamide riboside | 1件: D00036
D00036
| - | - | 1件: 97 97 |
304 | NICOTINE | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 3件: 6 6, 13, 84 |
305 | Nicotine dependence | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 13 13 |
306 | Nicotine gum | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 |
307 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 |
308 | Nicotine patch | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 2件: 6 6, 84 |
309 | Nicotine transdermal patch | 1件: Nicotine Nicotine | 1件: D03365
D03365
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 |
310 | Nicotinell | - | - | - | - | 1件: 6 6 |
311 | Nicotinell 17,5 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 |
312 | Nicotinell 35 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 |
313 | Nicotinic acid | 1件: Niacin Niacin | 1件: D00049
D00049
| - | - | 1件: 79 79 |
314 | Nifedipine | 1件: Nifedipine Nifedipine | 1件: D00437
D00437
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 50 50, 81 |
315 | Nifurtimox | 1件: Nifurtimox Nifurtimox | 1件: D00833
D00833
| - | - | 1件: 65 65 |
316 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: D00833
D00833
,
D07883
| 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 |
317 | Nifurtimox-Eflronithine Combination Treatment (NECT) | 1件: Nifurtimox Nifurtimox | 1件: D00833
D00833
| - | - | 1件: 65 65 |
318 | Nilotinib | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 5件: 6 6, 8, 34, 51, 86 |
319 | Nilotinib (Tasigna) | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 51 51 |
320 | Nilotinib 150 MG | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 8 8 |
321 | Nilotinib 150mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 |
322 | Nilotinib 300mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 |
323 | Nilotinib 50 mg | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
324 | NILOTINIB HYDROCHLORIDE MONOHYDRATE | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 |
325 | Nilvadipine | 1件: Nilvadipine Nilvadipine | 1件: D01908
D01908
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 |
326 | Nimenrix | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 50 50, 61 |
327 | Nimesulide | 1件: Nimesulide Nimesulide | 1件: D01049
D01049
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
328 | Ninlaro | 1件: Ixazomib Ixazomib | 1件: D10130
D10130
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 2件: 13 13, 61 |
329 | NINTEDANIB | 1件: Nintedanib Nintedanib | 1件: D10481
D10481
| 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 5件: 51 51, 85, 89, 227, 228 |
330 | Nintedanib 150 mg and 100 mg soft capsules | 1件: Nintedanib Nintedanib | 1件: D10481
D10481
| 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 227 227 |
331 | Nintédanib | - | - | - | - | 1件: 227 227 |
332 | NIP292 tablet | - | - | - | - | 1件: 85 85 |
333 | NIP292 tablets | - | - | - | - | 1件: 85 85 |
334 | Nipocalimab | 1件: Nipocalimab Nipocalimab | 1件: D11666
D11666
| 1件: FCGRT FCGRT 💬 | - | 6件: 11 11, 14, 46, 49, 53, 61 |
335 | Nitazoxanide | 1件: Nitazoxanide Nitazoxanide | 1件: D02486
D02486
| - | - | 3件: 46 46, 96, 97 |
336 | Nitazoxanide 500Mg Oral Tablet | 1件: Nitazoxanide Nitazoxanide | 1件: D02486
D02486
| - | - | 2件: 46 46, 97 |
337 | NITISINONE | 1件: Nitisinone Nitisinone | 1件: D05177
D05177
| 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 3件: 6 6, 164, 241 |
338 | Nitisinone 10 mg Tablet High Compritol | 1件: Nitisinone Nitisinone | 1件: D05177
D05177
| 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 |
339 | Nitisinone Baked Tablet | 1件: Nitisinone Nitisinone | 1件: D05177
D05177
| 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 |
340 | Nitrate | 1件: Nitrate Nitrate | 1件: D02313
D02313
| - | - | 4件: 58 58, 67, 113, 299 |
341 | Nitrate-depleted beetroot juice | 1件: Nitrate Nitrate | 1件: D02313
D02313
| - | - | 1件: 67 67 |
342 | NITRIC OXIDE | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 7件: 85 85, 86, 88, 210, 251, 294, 299 |
343 | Nitric Oxide 160 ppm | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 299 299 |
344 | Nitric Oxide for inhalation | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 2件: 86 86, 299 |
345 | Nitric Oxide generated by the GeNO nitrosyl delivery system | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 86 86 |
346 | Nitric Oxide plus Oxygen | 2件: Nitric Oxide Nitric Oxide, Oxygen | 2件: D00003
D00003
,
D00074
| - | - | 1件: 86 86 |
347 | Nitric oxide supplement | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 251 251 |
348 | Nitrite | 1件: Nitrite Nitrite | - | - | - | 2件: 58 58, 86 |
349 | Nitrofurantoin | 1件: Nitrofurantoin Nitrofurantoin | 1件: D00439
D00439
| - | - | 1件: 13 13 |
350 | Nitrogen | 1件: Nitrogen Nitrogen | 1件: D00083
D00083
| - | - | 5件: 5 5, 6, 17, 211, 299 |
351 | Nitroglycerin | 1件: Nitroglycerin Nitroglycerin | 1件: D00515
D00515
| - | - | 1件: 51 51 |
352 | Nitroglycerin Ointment 2% | 1件: Nitroglycerin Nitroglycerin | 1件: D00515
D00515
| - | - | 1件: 51 51 |
353 | Nitroglycerine | 1件: Nitroglycerin Nitroglycerin | 1件: D00515
D00515
| - | - | 2件: 46 46, 51 |
354 | Nitroglycerine gel | 1件: Nitroglycerin Nitroglycerin | 1件: D00515
D00515
| - | - | 1件: 51 51 |
355 | Nitroprusside | 1件: Nitroprusside Nitroprusside | - | - | - | 1件: 51 51 |
356 | Nitrosyl | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 86 86 |
357 | Nitrous Oxide | 1件: Nitrous oxide Nitrous oxide | 1件: D00102
D00102
| - | - | 1件: 34 34 |
358 | NiuBangZi pill | - | - | - | - | 1件: 46 46 |
359 | Nivolumab | 1件: Nivolumab Nivolumab | 1件: D10316
D10316
| 1件: PDCD1 PDCD1 💬 | 3件: Cell adhesion molecules Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬 | 12件: 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |
360 | NIZORAL | 1件: Ketoconazole Ketoconazole | 1件: D00351
D00351
| 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
361 | NK Cells | 1件: Natural Killer Cell Natural Killer Cell | - | - | - | 1件: 26 26 |
362 | Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH | - | - | - | - | 1件: 254 254 |
363 | Nle4-D-Phe7-alpha-MSH | - | - | - | - | 1件: 254 254 |
364 | NLX-112 | - | - | - | - | 1件: 6 6 |
365 | NLY01 | - | - | - | - | 1件: 6 6 |
366 | NM8074 | - | - | - | - | 2件: 62 62, 109 |
367 | NMDA | 1件: Ketamine Ketamine | 1件: D08098
D08098
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 |
368 | NN 1841 | - | - | - | - | 1件: 288 288 |
369 | NN-220 | - | - | - | - | 1件: 78 78 |
370 | NN1841 | - | - | - | - | 1件: 288 288 |
371 | NN8630 | - | - | - | - | 1件: 78 78 |
372 | NN8640 | - | - | - | - | 1件: 78 78 |
373 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 |
374 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 |
375 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 |
376 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 |
377 | NNC 126-0083 | - | - | - | - | 1件: 78 78 |
378 | NNC 142-0002 | - | - | - | - | 1件: 46 46 |
379 | NNC0109-0012 | - | - | - | - | 1件: 46 46 |
380 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 |
381 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 |
382 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 |
383 | NNC0142-0002 | - | - | - | - | 1件: 46 46 |
384 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 |
385 | NNC0195-0092 | - | - | - | - | 1件: 78 78 |
386 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 |
387 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 |
388 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 |
389 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 |
390 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 |
391 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 |
392 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 |
393 | NNC109-0012 | - | - | - | - | 1件: 46 46 |
394 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 |
395 | NNC142-0002 | - | - | - | - | 1件: 96 96 |
396 | NNC151-0000 | - | - | - | - | 1件: 46 46 |
397 | NNZ-2566 | - | - | - | - | 2件: 156 156, 206 |
398 | NNZ-2591 | 1件: NNZ-2591 NNZ-2591 | - | - | - | 1件: 201 201 |
399 | NO | - | - | - | - | 9件: 6 6, 46, 58, 62, 86, 97, 222, 299, 321 |
400 | Nolpitantium Besylate | - | - | - | - | 1件: 97 97 |
401 | NOMACOPAN | 1件: Nomacopan Nomacopan | 1件: D11473
D11473
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 162 162 |
402 | Nomacopan (rVA576) | 1件: Nomacopan Nomacopan | 1件: D11473
D11473
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 162 162 |
403 | Nomegestrol | 1件: Nomegestrol Nomegestrol | 1件: D07222
D07222
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
404 | Nomegestrol acetate | 3件: Acetate Acetate, Nomegestrol, Nomegestrol acetate | 2件: D07222
D07222
,
D08281
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
405 | Non applicabile | - | - | - | - | 4件: 13 13, 49, 51, 256 |
406 | Non applicable | - | - | - | - | 2件: 10 10, 19 |
407 | Non as of yet | - | - | - | - | 1件: 97 97 |
408 | Non ATG Conditioning regimen | - | - | - | - | 1件: 60 60 |
409 | NON COMMERCIAL | - | - | - | - | 1件: 75 75 |
410 | Non disponibile | - | - | - | - | 1件: 201 201 |
411 | Non intervention-Genetic testing | - | - | - | - | 1件: 6 6 |
412 | Non invasive prenatal diagnosis | - | - | - | - | 3件: 8 8, 113, 206 |
413 | NON PROPIETRY, THEREFORE N/A | - | - | - | - | 1件: 51 51 |
414 | Non-anti-TNF biologics | - | - | - | - | 2件: 46 46, 271 |
415 | Non-biologic anti-rheumatic drugs | - | - | - | - | 1件: 46 46 |
416 | Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | - | - | - | - | 1件: 46 46 |
417 | Non-Biologic DMARDs | - | - | - | - | 3件: 46 46, 86, 107 |
418 | Non-biological DMARDs | - | - | - | - | 1件: 46 46 |
419 | Non-enteric coated pancreatic enzyme preparation | - | - | - | - | 1件: 298 298 |
420 | Non-myeloablative Hematopoietic Stem Cell Transplantation | - | - | - | - | 1件: 93 93 |
421 | Non-nucleoside reverse transcriptase inhibitors | - | - | - | - | 1件: 265 265 |
422 | Non-pegylated interferon | - | - | - | - | 1件: 13 13 |
423 | Non-steroidal anti-inflammatory drug | - | - | - | - | 1件: 46 46 |
424 | Non-steroidal anti-inflammatory drug (NSAID) | - | - | - | - | 1件: 46 46 |
425 | Non-steroidal anti-inflammatory drugs | - | - | - | - | 1件: 46 46 |
426 | Non-steroidal anti-inflammatory drugs (NSAIDs) | - | - | - | - | 1件: 107 107 |
427 | Non-TNFi-biologic class | - | - | - | - | 1件: 46 46 |
428 | Nonbiologic DMARDs of investigator's choice | - | - | - | - | 1件: 46 46 |
429 | None | - | - | - | - | 20件: 6 6, 46, 51, 65, 66, 78, 84, 85, 96, 97, 140, 160, 161, 171, 222, 231, 246, 271, 299, 337 |
430 | None as of yet | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 1件: 46 46 |
431 | None assigned | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 2件: 231 231, 299 |
432 | None at this time | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 2件: 96 96, 140 |
433 | None given | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 1件: 97 97 |
434 | None yet | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 2件: 51 51, 222 |
435 | Norantipyrine | - | - | - | - | 1件: 2 2 |
436 | Nordilet® | - | - | - | - | 1件: 78 78 |
437 | Norditropin | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 195 |
438 | Norditropin 24 IU | 1件: Somatotropin Somatotropin | - | - | - | 1件: 195 195 |
439 | Norditropin FlexPro 10 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
440 | Norditropin FlexPro 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
441 | Norditropin FlexPro 10 mg/1.5 ml, solution for injection in pre-filled pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 195 195 |
442 | Norditropin FlexPro 5 mg/1.5 mL | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
443 | Norditropin FlexPro 5mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
444 | Norditropin Growth Hormone | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
445 | Norditropin NordiFlex® | - | - | - | - | 1件: 78 78 |
446 | Norditropin NordiFlex® 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
447 | Norditropin NordiFlex® 10mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
448 | Norditropin Simplex | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
449 | Norditropin SimpleXx | - | - | - | - | 5件: 3 3, 78, 107, 193, 195 |
450 | Norditropin SimplexX (5mg/1,5 ml) (INN:somatropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
451 | Norditropin SimpleXx (growth hormone) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
452 | Norditropin SimpleXx 10 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
453 | Norditropin SimpleXx 15 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 3 3 |
454 | Norditropin SimpleXx 5mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 107 |
455 | Norditropine simplex | - | - | - | - | 1件: 238 238 |
456 | Norditropin® | - | - | - | - | 2件: 78 78, 195 |
457 | Norditropin® FlexPro® | - | - | - | - | 1件: 78 78 |
458 | Norditropin® FlexPro® pen | - | - | - | - | 1件: 78 78 |
459 | Norditropin® SimpleXx® 5 mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
460 | Norepinephrine | 1件: Norepinephrine Norepinephrine | 1件: D00076
D00076
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 22 22, 296 |
461 | Norepinephrine Bitartrate | 1件: Norepinephrine Norepinephrine | 1件: D00076
D00076
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 296 296 |
462 | Norethindrone | 1件: Norethisterone Norethisterone | 1件: D00182
D00182
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 4件: 13 13, 46, 49, 299 |
463 | Norgestimate | 1件: Norgestimate Norgestimate | 1件: D05209
D05209
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 299 299 |
464 | Normal human immunoglobulin G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
465 | Normal Saline | - | - | - | - | 18件: 6 6, 13, 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 271, 276, 296, 299 |
466 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 |
467 | Normal Saline Enema | - | - | - | - | 1件: 97 97 |
468 | Normal Saline for Injection | - | - | - | - | 1件: 13 13 |
469 | Normal saline instillation | - | - | - | - | 1件: 226 226 |
470 | Normal saline IV, salt tablets | - | - | - | - | 1件: 299 299 |
471 | Normal saline solution | 1件: Sodium chloride Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 299 299 |
472 | Normal saline: | - | - | - | - | 1件: 299 299 |
473 | Normix | - | - | - | - | 1件: 96 96 |
474 | NORMIX*AD 12CPR RIV 200MG | - | - | - | - | 1件: 96 96 |
475 | Norovirus -specific T-cell (NST) therapy | - | - | - | - | 1件: 65 65 |
476 | Norphenazone | 1件: Edaravone Edaravone | 1件: D01552
D01552
| - | - | 1件: 2 2 |
477 | Norspan | - | - | - | - | 1件: 46 46 |
478 | Northera | 1件: Droxidopa Droxidopa | 1件: D01277
D01277
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
479 | Nortriptyline | 1件: Nortriptyline Nortriptyline | 1件: D08288
D08288
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 2件: 6 6, 226 |
480 | Nortriptyline hydrochloride | 1件: Nortriptyline Nortriptyline | 1件: D08288
D08288
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 6 6 |
481 | Norucholic acid | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 2件: 93 93, 94 |
482 | Norucholic acid (NCA) 500 mg | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 93 93 |
483 | NorUDCA | - | - | - | - | 1件: 94 94 |
484 | NorUDCA (Norursodeoxycholic acid) | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 |
485 | NorUrsodeoxycholic Acid | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 |
486 | Norursodeoxycholic acid, NCA | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 |
487 | Norvir | 1件: Ritonavir Ritonavir | 1件: D00427
D00427
| - | - | 2件: 265 265, 299 |
488 | Norvir 100 mg film-coated tablets | - | - | - | - | 1件: 299 299 |
489 | Novamin | - | - | - | - | 1件: 299 299 |
490 | Novantrone | 1件: Mitoxantrone Mitoxantrone | 1件: D08224
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
491 | NOVANTRONE*INF 2MG/ML 5ML | 1件: Mitoxantrone Mitoxantrone | 1件: D08224
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
492 | Novartis Pharmaceuticals Corporation | - | - | - | - | 1件: 13 13 |
493 | NOVATREX | - | - | - | - | 1件: 13 13 |
494 | Novo Rapid | - | - | - | - | 1件: 299 299 |
495 | Novo Rapid Insulin (Novonordisk) | - | - | - | - | 1件: 299 299 |
496 | Novolin-R insulin | - | - | - | - | 1件: 127 127 |
497 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 |
498 | NovoNorm 1 mg | - | - | - | - | 1件: 299 299 |
499 | NovoNorm 2 mg | - | - | - | - | 1件: 299 299 |
500 | Novorapid / humalog short acting insulin | - | - | - | - | 1件: 299 299 |
501 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 |
502 | NovoRapid Aspartate | - | - | - | - | 1件: 299 299 |
503 | NOX-E36 | - | - | - | - | 1件: 49 49 |
504 | Noxafil | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 3件: 60 60, 65, 299 |
505 | NOXAFIL - 40 mg/ml oral suspension | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 299 299 |
506 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 299 299 |
507 | NOXAFIL - oral suspension 40 mg/ml | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 299 299 |
508 | Noxafil 100 mg | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 299 299 |
509 | Noxafil 100 mg Tablets Gastro-Resistant | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 299 299 |
510 | Noxafil 40 mg/ml oral solution | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 65 65 |
511 | Noxafil Gastro resistant tablets | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 60 60 |
512 | Noxafil® | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 2件: 60 60, 299 |
513 | NP001 | - | - | - | - | 1件: 2 2 |
514 | NP031112 | - | - | - | - | 1件: 5 5 |
515 | NP031112 600mg | - | - | - | - | 1件: 5 5 |
516 | NP031112 800mg | - | - | - | - | 1件: 5 5 |
517 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 |
518 | NPC transplantation | - | - | - | - | 1件: 6 6 |
519 | NPC-02 | - | - | - | - | 1件: 171 171 |
520 | NPC-09 | - | - | - | - | 1件: 30 30 |
521 | NPC-12G gel | - | - | - | - | 2件: 34 34, 158 |
522 | NPC-12Y gel | - | - | - | - | 1件: 158 158 |
523 | NPC-14 | - | - | - | - | 1件: 113 113 |
524 | NPI-001 | - | - | - | - | 2件: 90 90, 303 |
525 | NPL-2009 | - | - | - | - | 1件: 206 206 |
526 | NPLATE | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
527 | NPLATE 500 microgramos polvo para solución inyectable | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
528 | NPSP 558 | - | - | - | - | 1件: 235 235 |
529 | NPSP558 | - | - | - | - | 1件: 235 235 |
530 | NR082 Injection | - | - | - | - | 1件: 302 302 |
531 | NR2B NMDA Antagonist CP-101,606 (traxoprodil) | 1件: Ketamine Ketamine | 1件: D08098
D08098
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 |
532 | NRTX-1001 | - | - | - | - | 1件: 141 141 |
533 | NS | - | - | - | - | 1件: 2 2 |
534 | NS 2330 | - | - | - | - | 1件: 6 6 |
535 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 |
536 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 |
537 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 |
538 | NS-304 Placebo | - | - | - | - | 2件: 70 70, 88 |
539 | NS2 | - | - | - | - | 1件: 160 160 |
540 | NS2330 | - | - | - | - | 1件: 6 6 |
541 | NSAID | - | - | - | - | 1件: 271 271 |
542 | NSAIDs | - | - | - | - | 4件: 46 46, 70, 107, 271 |
543 | NSAIDs (permitted,not necessary) | - | - | - | - | 1件: 46 46 |
544 | NSAIDs and sulfasalazine | 1件: Sulfasalazine Sulfasalazine | 1件: D00448
D00448
| - | - | 1件: 271 271 |
545 | NsNSAIDs | - | - | - | - | 2件: 107 107, 271 |
546 | NSP001 | - | - | - | - | 1件: 96 96 |
547 | NT 101 | - | - | - | - | 4件: 5 5, 6, 7, 17 |
548 | NT-501 | - | - | - | - | 2件: 90 90, 303 |
549 | NT-I7 | 1件: Efineptakin alfa Efineptakin alfa | 1件: D11957
D11957
| - | - | 1件: 25 25 |
550 | NT-KO-003 | - | - | - | - | 1件: 13 13 |
551 | NTBC | - | - | - | - | 1件: 241 241 |
552 | NTCELL Implantation | - | - | - | - | 1件: 6 6 |
553 | NTLA-2001 | - | - | - | - | 1件: 28 28 |
554 | NU100 | - | - | - | - | 1件: 13 13 |
555 | NUCALA | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 |
556 | Nucala 100 mg powder for solution for injection | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 |
557 | NUCALA® | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 |
558 | NuCel | - | - | - | - | 1件: 70 70 |
559 | NucleomaxX | - | - | - | - | 1件: 265 265 |
560 | Nucleoside analogue sparing HAART regimen | - | - | - | - | 1件: 265 265 |
561 | Nucleoside reverse transcriptase inhibitors | - | - | - | - | 1件: 265 265 |
562 | Nuedexta | - | - | - | - | 1件: 2 2 |
563 | Null | - | - | - | - | 16件: 6 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
564 | Nulojix | 1件: Belatacept Belatacept | 1件: D03222
D03222
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
565 | NurOwn (MSC-NTF cells) | - | - | - | - | 2件: 2 2, 13 |
566 | NurOwn® (MSC-NTF cells) | - | - | - | - | 1件: 2 2 |
567 | Nursinersen | - | - | - | - | 1件: 3 3 |
568 | NUSINERSEN | 1件: Nusinersen Nusinersen | 1件: D10881
D10881
| 1件: SMN2 SMN2 💬 | - | 1件: 3 3 |
569 | Nusinersen Injectable Product | 1件: Nusinersen Nusinersen | 1件: D10881
D10881
| 1件: SMN2 SMN2 💬 | - | 1件: 3 3 |
570 | NUSINERSEN SODIUM | 1件: Nusinersen Nusinersen | 1件: D10881
D10881
| 1件: SMN2 SMN2 💬 | - | 1件: 3 3 |
571 | Nusinersen Treatments | 1件: Nusinersen Nusinersen | 1件: D10881
D10881
| 1件: SMN2 SMN2 💬 | - | 1件: 3 3 |
572 | Nutraceutical Combination | - | - | - | - | 1件: 96 96 |
573 | Nutridrink-Impact | - | - | - | - | 1件: 299 299 |
574 | Nutrition supplement | - | - | - | - | 1件: 97 97 |
575 | Nutrition treat | - | - | - | - | 1件: 96 96 |
576 | Nutritional dietary intervention | - | - | - | - | 2件: 96 96, 97 |
577 | Nutritional Formulation Containing Exogenous Ketones | - | - | - | - | 1件: 201 201 |
578 | Nutritional Ketone Supplement | - | - | - | - | 1件: 317 317 |
579 | Nutritional Supplement | - | - | - | - | 1件: 90 90 |
580 | Nutritional supplementation standardized formula | - | - | - | - | 1件: 78 78 |
581 | NUTROPIN | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
582 | Nutropin AQ | - | - | - | - | 4件: 78 78, 134, 193, 299 |
583 | Nutropin AQ [somatropin (DNA origin) injection] | 1件: Somatotropin Somatotropin | - | - | - | 1件: 299 299 |
584 | NutropinAq | - | - | - | - | 1件: 78 78 |
585 | NutropinAq 10 mg/2 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
586 | NutropinAq 10 mg/2 ml (30 UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
587 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
588 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | - | - | - | 1件: 65 65 |
589 | NutropinAq 10mg/2ml solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 96 96 |
590 | NutropinAq® | 1件: Somatotropin Somatotropin | - | - | - | 1件: 96 96 |
591 | Nuvion®) | - | - | - | - | 1件: 97 97 |
592 | NV1205 | - | - | - | - | 1件: 20 20 |
593 | NVF233 | - | - | - | - | 1件: 13 13 |
594 | NW-1015 | - | - | - | - | 1件: 6 6 |
595 | NW-1015E, EMD 1195686, MSC2191632B | - | - | - | - | 1件: 6 6 |
596 | NX-13 250 mg | - | - | - | - | 1件: 97 97 |
597 | NX-13 250mg IR | - | - | - | - | 1件: 97 97 |
598 | NX-13 500mg IR | - | - | - | - | 1件: 97 97 |
599 | NX-13 500mg MR | - | - | - | - | 1件: 97 97 |
600 | NX1011 | - | - | - | - | 1件: 86 86 |
601 | NYX-458 | - | - | - | - | 1件: 6 6 |
602 | Nébivolol | - | - | - | - | 1件: 113 113 |